|
|
|
Hair Loss Study Abstract: Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers.
|
Title
Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens
in male volunteers.
Author
Gormley GJ; Stoner E; Rittmaster RS; Gregg H; Thompson DL; Lasseter KC; Vlasses PH;
Stein EA
Address
Merck, Sharp, and Dohme Research Laboratories, Rahway, New Jersey 07065.
Source
J Clin Endocrinol Metab, 70: 4, 1990 Apr, 1136-41
Abstract
Finasteride, a 5 alpha-reductase inhibitor, was administered to normal male volunteers
in a blinded placebo-controlled study at daily oral doses of 25, 50, and 100 mg for 11
days (part 1) and daily oral doses of 0.04, 0.12, 0.2, and 1.0 mg for 14 days (part 2).
Results from part 1 showed a significant reduction in dihydrotestosterone (DHT) at all
doses and a significant increase in both testosterone (T) and delta 4-androstenedione at
the 50- and 100-mg doses. No change was seen in LH, FSH, cortisol, or estradiol levels.
Serum lipids, including total cholesterol, low density lipoprotein, high density
lipoprotein, and triglycerides were not affected by treatment. Results from part 2 again
showed significant reduction in DHT at all doses. DHT levels returned to pretreatment
values within 14 days of discontinuing treatment. Significant increases in T were observed
only in the 1.0 mg group and only during the first 8 days of treatment. The T/DHT ratio
increased with all doses and returned to baseline when drug was discontinued. The DHT
metabolites and androstanediol glucuronide and androsterone glucuronide were significantly
reduced at all doses. There were no significant adverse experiences reported during part 1
or 2. In conclusion, finasteride is well tolerated by normal volunteers and results in
significant suppression of serum DHT at all doses tested.
Language of Publication
English
Unique Identifier
90203145
content2 |
|
